Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate
South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in the nation’s advanced therapeutics landscape with the full regulatory approval of RIMQARTO® Inj. (anbalcabtagene autoleucel). Granted by the Ministry of Food and Drug Safety (MFDS) on April 29, the decision marks the first time a domestically developed chimeric antigen receptor (CAR) T-cell therapy has been successfully commercialized by a Korean company. The approval underscores the growing maturity of South Korea’s cell and gene therapy ecosystem and highlights the country’s ability to innovate in one of the most complex and cutting-edge areas of modern medicine.
RIMQARTO® now becomes the 42nd domestically developed therapeutic authorized under the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products. This designation reflects not only regulatory endorsement but also the culmination of years of scientific research, clinical development, and coordinated support from government-backed initiatives designed to accelerate innovation in regenerative medicine and advanced biologics.
At its core, CAR T-cell therapy represents a highly personalized form of immunotherapy. The process involves collecting a patient’s own T cells, genetically modifying them in a laboratory to recognize and attack cancer cells, and then reinfusing the engineered cells back into the patient. Unlike conventional therapies such as chemotherapy or radiation, which can affect both healthy and malignant cells, CAR T-cell therapy is designed to selectively target tumor cells, offering the potential for more precise and durable responses.
RIMQARTO® distinguishes itself within this therapeutic class as a next-generation CD19-targeting CAR T-cell therapy enhanced by Curocell’s proprietary OVIS™ (Overcome Immune Suppression) technology. One of the major limitations of earlier CAR T-cell therapies has been the phenomenon known as T-cell exhaustion, in which engineered immune cells lose their effectiveness over time due to immunosuppressive signals within the tumor microenvironment. OVIS™ is specifically designed to counteract these suppressive pathways, thereby sustaining T-cell activity and improving long-term anticancer efficacy. By addressing this critical challenge, RIMQARTO® aims to deliver more durable and consistent treatment outcomes for patients.
The therapy has been approved for adult patients with relapsed or refractory forms of aggressive B-cell lymphomas, including Diffuse Large B-Cell Lymphoma (DLBCL) and Primary Mediastinal Large B-Cell Lymphoma (PMBCL), who have previously undergone at least two lines of systemic therapy. These patient populations often face limited treatment options and poor prognoses, making the availability of innovative therapies such as CAR T-cell treatments particularly significant.
The regulatory approval of RIMQARTO® was supported by data from a pivotal Phase 2 clinical trial that demonstrated compelling efficacy results. The study reported an objective response rate (ORR) of 75.3%, indicating that a substantial proportion of patients experienced a measurable reduction in tumor burden. Even more notably, the complete response (CR) rate reached 67.1%, suggesting that many patients achieved the disappearance of detectable cancer following treatment. These outcomes are especially encouraging in a heavily pretreated population where therapeutic options are typically limited and response rates are often modest.
Safety data from the trial further reinforced the therapy’s clinical profile. CAR T-cell therapies are commonly associated with certain immune-related adverse events, most notably cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In the RIMQARTO® study, CRS was observed in 10% of patients, while ICANS occurred in 5%. These rates are relatively manageable compared to historical data from earlier CAR T-cell therapies, suggesting that the treatment may offer a favorable balance between efficacy and safety when administered under appropriate clinical supervision.
Interestingly, RIMQARTO® was initially submitted for conditional approval; however, during the review process, the MFDS determined that Phase 3 trial data would not be required for full approval. This decision reflects both the urgent unmet medical need in third-line lymphoma treatment and the recognition of RIMQARTO® as a novel and promising therapeutic option. Similar to other CAR T-cell therapies approved globally, the authorization is contingent upon continued long-term follow-up studies and the implementation of risk management plans to monitor safety and efficacy in real-world settings.
The successful development and approval of RIMQARTO® were made possible through a combination of regulatory innovation and strong governmental support. The therapy benefited from funding and strategic backing provided by the Ministry of Health and Welfare (MOHW) and the Korea Drug Development Fund, both of which play pivotal roles in fostering pharmaceutical innovation within the country. Additionally, the MFDS’s “Bio-Challenger Program” and the “Global Innovative Products on Fast Track” (GIFT) designation helped streamline the development and review processes, significantly reducing the time required to bring the therapy from concept to approval.
RIMQARTO® was also selected for participation in the MOHW’s “Concurrent Pilot Program for Approval-Evaluation-Negotiation,” an initiative aimed at accelerating patient access to new therapies by aligning regulatory approval with reimbursement evaluation processes. This program is expected to shorten the timeline for RIMQARTO® to be listed under South Korea’s national health insurance system, thereby improving accessibility for eligible patients.
Curocell’s Chief Executive Officer, Kim Gun-soo, described the approval as a historic achievement for the country’s pharmaceutical and biotechnology sectors. He emphasized that the milestone reflects years of dedication to advancing CAR T-cell technology domestically, particularly at a time when such capabilities were not yet established in South Korea. According to Kim, the company’s success demonstrates the potential for Korean innovation to compete on a global stage in highly sophisticated therapeutic areas.
Looking ahead, Curocell plans to build upon the success of RIMQARTO® through a multifaceted growth strategy. This includes expanding the therapy’s indications into additional hematologic malignancies, pursuing entry into international markets, and advancing next-generation pipeline candidates. The company is also exploring the application of its CAR T-cell platform in solid tumors and autoimmune diseases—areas that present significant scientific challenges but also substantial opportunities for innovation.
The expansion into solid tumors is particularly noteworthy, as CAR T-cell therapies have historically shown limited efficacy in these cancers due to factors such as the immunosuppressive tumor microenvironment and physical barriers to T-cell infiltration. By leveraging its OVIS™ technology, Curocell aims to overcome these obstacles and unlock new therapeutic possibilities. Similarly, the exploration of CAR T-cell applications in autoimmune diseases represents an emerging frontier, where engineered immune cells could potentially be used to reset dysregulated immune systems.
In summary, the approval of RIMQARTO® represents a transformative moment for both Curocell and South Korea’s biopharmaceutical industry. As the country’s first domestically developed and commercialized CAR T-cell therapy, it not only addresses a critical unmet need in oncology but also sets the stage for future innovations in cell and gene therapy. With strong clinical data, supportive regulatory frameworks, and a clear vision for expansion, RIMQARTO® has the potential to become a cornerstone of next-generation cancer treatment while elevating South Korea’s position in the global biotechnology arena.
Source Link:https://www.businesswire.com/
